AR021876A1 - COMBINATION THERAPY FOR HCV INDUCTION OF RIBAVIRINA - INTERFERON ALFA PEGILADO - Google Patents
COMBINATION THERAPY FOR HCV INDUCTION OF RIBAVIRINA - INTERFERON ALFA PEGILADOInfo
- Publication number
- AR021876A1 AR021876A1 ARP990106462A ARP990106462A AR021876A1 AR 021876 A1 AR021876 A1 AR 021876A1 AR P990106462 A ARP990106462 A AR P990106462A AR P990106462 A ARP990106462 A AR P990106462A AR 021876 A1 AR021876 A1 AR 021876A1
- Authority
- AR
- Argentina
- Prior art keywords
- interferon alfa
- effective amount
- weeks
- hcv
- therapeutically effective
- Prior art date
Links
- 108010047761 Interferon-alpha Proteins 0.000 title abstract 5
- 102000006992 Interferon-alpha Human genes 0.000 title abstract 5
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title abstract 4
- 229950000038 interferon alfa Drugs 0.000 title abstract 4
- 230000006698 induction Effects 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 229960000329 ribavirin Drugs 0.000 abstract 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 3
- 208000020403 chronic hepatitis C virus infection Diseases 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se revela el uso de ribavirina e interferon alfa pegilado para la manufactura de composiciones farmacéuticas para tratar un paciente con infeccion cronicade hepatitis C, por ejemplo un paciente que tiene un genotipo 1,2 o 3 de VHC, para erradicar elARN del VHC detectable, mediante un método que comprende laadministracion de una cantidad efectiva de ribavirina en asociacion con una cantidad efectiva de interferon alfa pegilado, que se caracteriza en que eltratamiento de los pacientes que tieneninfecciones cronicas de hepatitis C se efectua en dos períodos de tratamiento;(a)un primer período de tratamiento de almenos 20 a 30 semanas, en el cual se administran una cantidad terapéuticamente efectiva de ribavirina y una cantidad dosificantede induccion terapéuticamenteefectiva de interferon alfa pegilado, por ejemplo, interferon alfa-2b pegilado suficiente para al menos disminuir sustanciamente, y preferentemente paraerradicar el ARN de VHC detectable; y b) un segundo período detratamie nto de al menos de 20 a 30 semanas, donde una cantidad terapéuticamente efectiva deribavirina y una cantidad terapéuticamente efectiva de interferon alfa pegilado se administran en forma suficiente para mantener el ARN del VHC nodetectable,durante a l menos de 20 a 30 semanas luego de finalizar el primer período de tratamiento y para mantener el ARN del VHC no detectable durante al menos 24semanas, luego de finalizar el segundo período de tratamiento.The use of pegylated ribavirin and interferon alfa is disclosed for the manufacture of pharmaceutical compositions for treating a patient with chronic hepatitis C infection, for example a patient who has a 1.2 or 3 HCV genotype, to eradicate detectable HCV RNA, by a method comprising administering an effective amount of ribavirin in association with an effective amount of pegylated interferon alfa, which is characterized in that the treatment of patients who have chronic hepatitis C infections is carried out in two treatment periods; (a) a first treatment period of at least 20 to 30 weeks, in which a therapeutically effective amount of ribavirin and a dosing amount of therapeutically effective induction of pegylated interferon alpha are administered, for example, pegylated interferon alfa-2b sufficient to at least substantially decrease, and preferably to eradicate HCV RNA detectable; and b) a second treatment period of at least 20 to 30 weeks, where a therapeutically effective amount of deribavirin and a therapeutically effective amount of pegylated interferon alfa are administered sufficiently to keep the HCV RNA nodetectable, for at least 20 to 30 weeks after the end of the first treatment period and to keep HCV RNA undetectable for at least 24 weeks, after the end of the second treatment period.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21587698A | 1998-12-18 | 1998-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR021876A1 true AR021876A1 (en) | 2002-08-07 |
Family
ID=22804768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990106462A AR021876A1 (en) | 1998-12-18 | 1999-12-16 | COMBINATION THERAPY FOR HCV INDUCTION OF RIBAVIRINA - INTERFERON ALFA PEGILADO |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1140143A2 (en) |
| JP (1) | JP2003507322A (en) |
| AR (1) | AR021876A1 (en) |
| AU (1) | AU2157000A (en) |
| CA (1) | CA2354536A1 (en) |
| PE (1) | PE20001369A1 (en) |
| WO (1) | WO2000037110A2 (en) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| NZ547204A (en) | 2000-05-26 | 2008-01-31 | Idenix Cayman Ltd | Methods and compositions for treating flaviviruses and pestiviruses |
| CA2413258C (en) * | 2000-06-30 | 2012-01-03 | Zymogenetics, Inc. | Interferon-like protein zcyto21 |
| KR100851861B1 (en) * | 2000-08-07 | 2008-08-13 | 사이클론 파아머슈티컬 인코오퍼레이티드 | Treatment of hepatitis c with thymosin, interferon and ribavirin |
| US7208167B2 (en) | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
| AU2002213343A1 (en) * | 2000-10-18 | 2002-04-29 | Schering Corporation | Ribavirin-pegylated interferon alfa HCV combination therapy |
| US7910313B2 (en) | 2001-04-20 | 2011-03-22 | Zymogenetics, Inc. | Cytokine protein family |
| DE60237791D1 (en) | 2001-04-20 | 2010-11-04 | Bristol Myers Squibb Co | Zytokinproteinfamilie |
| US7138376B2 (en) | 2001-09-28 | 2006-11-21 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| MY140819A (en) | 2002-06-28 | 2010-01-29 | Idenix Caymans Ltd | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae |
| AU2003248748A1 (en) | 2002-06-28 | 2004-01-19 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| US7824851B2 (en) | 2002-11-15 | 2010-11-02 | Idenix Pharmaceuticals, Inc. | 2′-branched nucleosides and Flaviviridae mutation |
| KR20050109918A (en) | 2002-12-12 | 2005-11-22 | 이데닉스 (케이만) 리미티드 | Process for the production of 2'-branched nucleosides |
| CA2734052A1 (en) | 2003-05-30 | 2005-01-13 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| RU2371195C2 (en) * | 2003-08-13 | 2009-10-27 | Говард Дж. Смит Энд Эссошиэйтс Пти Лтд | Method of virus infection treatment |
| CN101023094B (en) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives |
| BRPI0515279A (en) | 2004-09-14 | 2008-07-15 | Pharmasset Inc | preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| ATE519503T1 (en) * | 2007-09-14 | 2011-08-15 | Schering Corp | METHOD FOR TREATING PATIENTS WITH HEPATITIS C |
| TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| US8716262B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| EP2376514A2 (en) | 2008-12-23 | 2011-10-19 | Pharmasset, Inc. | Nucleoside analogs |
| WO2010075554A1 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Synthesis of purine nucleosides |
| WO2010117936A1 (en) * | 2009-04-06 | 2010-10-14 | Schering Corporation | Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent |
| TWI583692B (en) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| RS54368B1 (en) | 2010-03-31 | 2016-04-28 | Gilead Pharmasset Llc | CRYSTAL (S) -ISOPROPYL 2 - ((((S) - ((((2R, 3R, 4R, 5R) -5- (2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1- (2H) -IL) - 4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-IL) METOXY) (PHENOXY) PHOSPHORYL) AMINO) PROPANOATE |
| CA2818853A1 (en) | 2010-11-30 | 2012-06-07 | Gilead Pharmasset Llc | 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus |
| UA116087C2 (en) | 2011-09-16 | 2018-02-12 | Гіліад Фармассет Елелсі | Methods for treating hcv |
| EA201490837A1 (en) | 2011-10-21 | 2014-11-28 | Эббви Инк. | METHODS OF TREATING HCV, INCLUDING, AT THE LITERATURE, TWO ANTI-VIRAL AGENTS OF DIRECT ACTION, RIBAVIRIN, BUT NOT INTERFERON |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| AU2013201532B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| MY172166A (en) | 2013-01-31 | 2019-11-15 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| SG11201600919UA (en) | 2013-08-27 | 2016-03-30 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| EA201892448A1 (en) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| DE69810822T2 (en) * | 1997-09-21 | 2003-11-20 | Schering Corp., Kenilworth | Combination therapy for the removal of detectable HCV-RNA in patients with chronic hepatitis C infection |
| CA2331823A1 (en) * | 1998-05-15 | 1999-11-25 | Schering Corporation | Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection |
-
1999
- 1999-12-16 AR ARP990106462A patent/AR021876A1/en unknown
- 1999-12-16 AU AU21570/00A patent/AU2157000A/en not_active Abandoned
- 1999-12-16 WO PCT/US1999/027935 patent/WO2000037110A2/en not_active Ceased
- 1999-12-16 CA CA002354536A patent/CA2354536A1/en not_active Abandoned
- 1999-12-16 JP JP2000589220A patent/JP2003507322A/en active Pending
- 1999-12-16 EP EP99965894A patent/EP1140143A2/en not_active Withdrawn
- 1999-12-17 PE PE1999001292A patent/PE20001369A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1140143A2 (en) | 2001-10-10 |
| WO2000037110A3 (en) | 2000-09-14 |
| JP2003507322A (en) | 2003-02-25 |
| PE20001369A1 (en) | 2000-12-09 |
| WO2000037110A2 (en) | 2000-06-29 |
| CA2354536A1 (en) | 2000-06-29 |
| AU2157000A (en) | 2000-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR021876A1 (en) | COMBINATION THERAPY FOR HCV INDUCTION OF RIBAVIRINA - INTERFERON ALFA PEGILADO | |
| CO4940414A1 (en) | THERAPY OF MODIFIED POLYETHYLENE GLYCOL INTERFERONS | |
| NZ507621A (en) | HCV-RNA eradication in antiviral treatment naive patients having HCV genotypes 1, 2 or 3 using ribavirin and interferon alpha combination therapy | |
| ES2186660T3 (en) | COMBINATION THERAPY TO ERADICATE HCV-RNA DETECTABLE IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION. | |
| AR023541A1 (en) | HCV COMBINATION THERAPY | |
| AR021226A1 (en) | COMBINATORY THERAPY WITH RIBAVIRINA-INTERFERON ALFA TO ERADICATE DETECTABLE HCV-RNA IN THOSE PATIENTS WHO PRESENT INFECTION WITH CHRONIC HEPATITIS C | |
| TW200716095A (en) | Method of treating interferon non-responders using HCV protease inhibitor | |
| BR0114636A (en) | Pegylated interferon-alpha / ribavirin hcv combination therapy | |
| BR9911076A (en) | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis C | |
| PL1778272T3 (en) | Use of a combination of cyclosporin and pegylated interferons for treating hepatitis c (hcv) | |
| EA201000085A1 (en) | dsPHK INTRODUCED FOR THE TREATMENT OF VIRAL INFECTION | |
| AR022116A1 (en) | COMBINATION THERAPY FOR RHCAVIRINE INDUCTION HCV - INTERFERON ALFA | |
| MD990258A (en) | Method of treatment of the acute viral hepatitis B | |
| MD2549F1 (en) | Method of treatment of the chronic viral hepatitis C | |
| CY1106388T1 (en) | THERAPY OF HEPATITIS C WITH THYMOSIN, INTEPHON, AND RIBAVIRIN | |
| JP2004529158A5 (en) | ||
| DK1311286T3 (en) | Treatment of hepatitis C with thymosin and pegylated interferon | |
| ECSP993178A (en) | COMBINATORY THERAPY WITH RIBARVIRINE-INTERFERON ALPHA TO ERADICATE HCV-DETECTABLE RNA IN THOSE PATIENTS WITH CHRONIC HEPATITIS C INFECTION | |
| TH33755A (en) | Combined therapy to eliminate detectable HCV-RNA in patients with chronic hepatitis C infection. | |
| TH53874A3 (en) | Combined HCV therapy by induction of ribavirin and pegilate-type interferon alpha. | |
| FR2791894B1 (en) | USE OF INTERFERON BETA IN THE TREATMENT OF EWING'S TUMOR | |
| TH87484A (en) | PEG-IFN Alpha and Ribavirin for HBV Treatment | |
| ECSP982669A (en) | COMBINATION THERAPY TO ERADICATE DETECTABLE HCV-RNA IN PATIENTS WITH CHRONIC HETATITIS C INFECTION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |